## **Supplementary Information**

#### Title

## CstF-64 and 3'UTR *cis*-element determine Star-PAP specificity for target mRNA selection by excluding PAPα

# Divya T. Kandala, Nimmy Mohan, Vivekanand A, Sudheesh AP, Reshmi G, and Rakesh S. Laishram $^{\#}$

*Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Trivandrum - 014, India* <sup>#</sup> *Corresponding Author* 

Running Title: Specificity mechanisms of nuclear poly(A) polymerase Star-PAP

<sup>#</sup>Corresponding Address:
Rakesh S. Laishram
Rajiv Gandhi Centre for Biotechnology
Thycaud Post, Poojappura
Trivandrum – 695014, India
E mail: <u>laishram@rgcb.res.in</u>
Phone: +91-0471-2529592

#### **List of Antibodies:**

Mouse monoclonal anti-FLAG M2 (Sigma), Rabbit monoclonal anti-FLAG (Sigma), Rabbit polyclonal anti-CPSF1 (Bethyl Lab), Rabbit polyclonal anti-CPSF2 (Bethyl lab), Rabbit polyclonal anti-CPSF3 (Bethyl lab), Rabbit polyclonal anti-CPSF4 (Bethyl lab), Rabbit polyclonal anti-CSTF2 (Bethyl lab), Rabbit Polyclonal anti-CSTF2T (Bethyl lab), Rabbit monoclonal anti-β-Tubulin (Novus), Mouse monoclonal anti-Actin (Novus), Mouse monoclonal anti-Gst tag antibody (Cell Biolabs), Rabbit polyclonal anti-PIPKIα (Mellman et al, 2008), Rabbit polyclonal anti-Star-PAP (Mohan et. al. 2015), Rabbit polyclonal anti-PAPOLA (Bethyl lab), Rabbit polyclonal anti-hFIP1 (Bethyl), Mouse monoclonal anti-NQO1 (Novus), Rabbit polyclonal anti-RNA Polymerase II (Bethyl lab), Goat polyclonal anti-BIK (Santa Cruz).

#### Gene specific forward primers used for 3'-RACE:

- 1. *HMOX1* 5'-CATCCTCAGTTCCTGCAGCA-3'
- 2. NQO1 5'-AAAACACTGCCCTCTTGTGG-3'
- 3. *GAPDH* 5'-TTTGGCTACAGCAACAGGGT-3'
- 5. *BIK* 5'-GCTGGAACACTGCTGAGGTT-3'

#### Primers used for 3'-end cleavage:

- 1. NQO1
   Clv FP: 5'-TGCCTTCATCTTCACTGCAA-3'

   Clv RP: 5'-TTGTCAAGCCAGTCACCAAG-3
- 2. *GCLC* Clv FP: 5'-ATGCCTGGTTTTCGTTTGCA-3'

## Clv RP: 5'-AGCTGTGGAACTCACACACACTCA-3'

- 3. *GAPDH* Clv FP: 5'-CACACTGAATCTCCCCTCCT-3' Clv RP: 5'-TTGACACAAGCCCAGCTTC-3'
- 4. *BIK* Clv FP: 5'-GCCCTCGGCAAAGAATCTAC- 3' Clv RP: 5'-CCTTTTGCAGGGAAGGATCT-3'

## **Primers for RIP analysis:**

1. NQO1	FP: 5'-TGCTCTCGACAGTATCCACAA-3'	
	RP: 5'-AGTTGTCAAGCCAGTCACCAA-3'	
2. GAPDH	FP: 5'-CACACTGAATCTCCCCTCCT-3'	
	RP: 5'-TTGACACAAGCCCAGCTTC-3'	
3. <i>BIK</i>	FP: 5'-TCTTGATGGAGACCCTCCTG-3'	
	RP: 5'-GTCCTCCATAGGGTCCAGGT-3'	
4. SV40	FP: 5'- CCCCCTGAACCTGAAACATA-3'	
	RP: 5'- TTGGACAAACCACAACTAGAATG-3'	

## Primers used in quantitative real time PCR:

1. HMOXI	FP: 5'-CCACCAAGTTCAAGCAGCTCTA -3'
	RP: 5'-GCTCCTGCAACTCCTCAAAGAG-3'
2. <i>BIK</i>	FP: 5'-TCTTGATGGAGACCCTCCTG-3'
	RP: 5'-GTCCTCCATAGGGTCCAGGT-3'
3. GCLC	FP: 5'-AAGTTCTTGAAACTCTGCAAGAGAAGG-3'
	RP: 5'-GCCTCAACTGTATTGAACTCGGAC-3'

4.	GAPDH	FP: 5'-GAAGGTCGGAGTCAACGGATTT-3'
		RP: 5'-GAATTTGCCATGGGTGGAAT-3'
5.	NQO1	FP: 5'-GAACTTCAATCCCATCATTTCCAG-3'
		RP: 5'-CAGCTTCTTTTGTTCAGCCACAAT-3'
6.	NOS2	FP: 5'-CTCAGCTCATCCGCTATGCT-3'
		RP: 5'-TCAGGTGGGATTTCGAAGAG-3'
7.	FLAG-NQO1	FP: 5'-ATGGATTACAAGGATGACGACG-3'

RP: 5'-CCTCCTTCATGGCATAGTTGAA-3'

#### siRNA Oligos used:

- 1. Control scrambled non-targeting: AGGUAGUGUAAUCGCCUUG
- 2. Star-PAP: GUGUGUUUGUCAGUGGCUU
- 3. CSTF2: GUUAGAUGCCAGAGGAUUA
- 4. CSTF2T: CCAUUAUUGACUCACCCUA
- 5. CPSF1: On target Smart pool (Dharmacon)
- 6. PAPa: GGAGACUGACUGCGUACUU
- 7. PAPy: GCUGGUGGUUCUUGGUAAA

### Supplementary Figure Legend:

**Supplementary Figure 1**: (A) UTR RNA sequences of various Star-PAP target and non-target mRNAs; Star-PAP binding USE region, -AUA- binding motif, poly(A) signal, cleavage site and downstream sequence element (DSE) are indicated. (B) EMSA experiment of *BIK* UTR RNA

with His-Star-PAP in presence and absence of Star-PAP antibody, (C) EMSA of *BIK* UTR RNA with Star-PAP in presence of 100-fold excess of non-radiolabelled specific (S) and non-specific (N) RNA, (D) Competition experiment of *NQO1* RNA in EMSA experiment as in C. F- free probe, B- Star-PAP-RNA binary complex, T- Star-PAP-RNA-Antibody ternary complex.

**Supplementary Figure 2**: (A) Schematic of *NQO1* UTR sequence showing Star-PAP binding USE region, suboptimal DSE, and Star-PAP binding and DSE mutations, (B) Specific (S) and non-specific (N) competitions in EMSA of *GCLC* with His-CstF-64 as in Suppl. Fig 1C, (C-D) EMSA of *NQO1* PAS and mutant DSE (U-rich DSE insertion, D-Mut) with increasing His-CstF-64 as in Fig. 4B, (E-F) Specific and non-specific competitions in EMSA of *NQO1* and *BIK* downstream mutant UTR RNA with His-CstF-64 as in <u>B</u>. F- free probe, B- Star-PAP-RNA binary complex.

**Supplementary Figure 3**: Reporter assay using mini-gene FLAG-NQO1 construct. (A) Schematic of *NQO1* UTR with three poly(A) sites, distal site that controls overall NQO1 expression and regulated by Star-PAP is referred as *NQO1* PAS in this paper.(B) Reporter FLAG-NQO1 expression from the reporter constructs as in Fig. 3J with different poly(A) sites of *NQO1* UTR (proximal, middle, distal, or full length UTR having all three polyA sites). Distinct poly(A) site driven FLAG-NQO1 reporter constructs were made by introducing respective mutations at the AAUAAA poly(A) signals as appropriate on the full length *NQO1* UTR. *SV40* UTR was used as a control in the reporter expression experiments. (C) FLAG-NQO1 expression from various reporter constructs as in B after Star-PAP knockdown. (D) Schematic of FLAG-NQO1 reporter construct driven by Star-PAP regulated distal poly(A) site (*NQO1* PAS) that controls overall NQO1 protein expression, or control reporter with *SV40* UTR construct. (E-F) Reporter assay of FLAG-NQO1 with *NQO1* PAS (WT), Star-PAP independent construct of

*NQO1* PAS with AUA mutation and U-rich DSE insertion (DU-Mut), or full-length *NQO1* UTR having all three poly(A) sites (FL) after knockdown of PAP $\alpha$ , PAP $\gamma$  or Star-PAP, and CstF-64 or CstF-64 $\tau$  as indicated. Westerns for respective knockdowns as well as loading control  $\beta$ -tubulin is also shown. (G) 3'-RACE assay of FLAG-NQO1 reporter from total RNA isolated from the cell after transfection of the reporter constructs in the presence and absence of Star-PAP knockdown, (H) Reporter assay of FLAG-NQO1 by Western blot using anti-FLAG antibody under the conditions as indicated, (I) Measurement of cleavage efficiency using a pair of primers across the cleavage site of the reporter NQO1 and total mRNA expression using a pair of primer from FLAG and NQO1 reading frame under the conditions indicated. (J-K) Reporter expression of the Star-PAP independent *NQO1* PAS mutant (DU Mut) after PAP $\alpha$  knockdown and rescue experiment with exogenous expression of PAP $\alpha$ , PAP $\gamma$  and Star-PAP, or after CstF-64 knockdown and rescue experiment with exogenously expressed CstF-64 $\tau$ . Wherever (–) siRNA is indicated, we have used control scrambled siRNA.

**Supplementary Figure 4**: Western blots showing knockdown of (A) Star-PAP, (B) PAP $\alpha$ , (C) CPSF-160, (D) CstF-64, (E) PAP $\gamma$ , and (F) CstF-64 $\tau$  in HEK 293 cells. (G) Actin protein level after knockdown of several 3'-end processing factors. Knockdown blots are shown in A-F. (H) Coommassie stained gel showing purified His-Star-PAP and (I) His-CstF-64.

**Supplementary Figure 5**: *In silico* analysis of -AUA- containing sequences genome wide on Star-PAP target genes (A) Line plot of -AUA- motif occurrence among Star-PAP target genes in the putative Star-PAP binding region (from -50 to -150 upstream of polyA site) showing the position of occurrence. The list of genes and position of AUA and their frequency of occurrence is shown in Suppl. Table 1. (B) Similar line plot as in A using a negative set of randomly selected Star-PAP non-regulated genes. (C) 12-most frequently occurring 5-mers (from the total possible 48 sequence having AUA) that occurred in >55% of the genes, (D) Top 15-most commonly observed 7-mers with central AUA motif and the corresponding p-values. Enrichment of -AUAU- motif is indicated.

**Supplementary Table 1:** Occurrence of -AUA- along with their position and frequency from Star-PAP regulated genes within the putative Star-PAP binding region (-50 to -150 upstream of polyA site).

**Supplementary Table 2**: List of 5-mers and 7-mers along with the confidence 7-mer obtained from the most frequently occurring 5-mers along with their frequency of occurrences in the dataset.

ВІК	CAUUCACUCCUGCCCCUGCCCACACGGCAGGUAGCAGGGGGAGUGCUGGUCACACCCCU Star-PAP binding region
NQO1	-120
Control Non Target	ACCAGAUCAAAGCUAGAAAAUGAGAUUCCUUAGCCUGGAUUUCCUUCUAACAUGUUAU- Star-PAP non-binding CAAAUCUGGGUAUCUUUCCAGGCUUCCCUGACUUGCUUUAGUUUUUAAGAUUUGUGUUUUUC UUUUUCCACAAGGAAUAAAUGAGAGGGAAUCGACUGUAUUCGUGCAUUUUUGGAUCAUUUU PAS CS DSE with CstF binding Sequence-
GCLC	ACAUGCAUUUUGGAUGAUUAAAGAAUGCCUGGUUUUCGUUUGCAAUUUGCUUGUGUAAAU- 60 CAGGUUGUAAAAAAGGCAGAUAAAUUGAAAUGUUUGUGGUAUGAGGAAAUAAAAGAAUGGAA UUAGCUUUCAGAAACCUUUGAGUGUGUGUGUGGGUUCCACAGCUAAACAAAUAGUAGAAG AGUUUGGUUUUUGUAA

- S N N Competition

+ + + Star-PAP

₹B

1 2 3 4 5 Lane

B BIK WT

F



F

+

Antibody Star-PAP

₹T

₹B

Lane

+

+

+

1234





NQO1 PAS

USE Star-PAP binding motif PAS CS DSE UTR --UGGGUGUUUCAGUUUGAAA<u>AUA</u>UUUUGUUGCCUU---AAUAAA----G---CAGUGAAGCUAAUGAUAGUG-- WT --UGGGUGUUUCAGUUUGAAA<u>GGG</u>UUUUGUUGCCUU---AAUAAA----G---CAGUGAAGCUAAUGAUAGUG-- U-Mut --UGGGUGUUUCAGUUUGAAA<u>AUA</u>UUUUUGUUGCCUU---AAUAAA----G---CAGUGAAUUUUUUGAUAGUG-- D-Mut



## **Supplementary Figure 3**



#### **Supplementary Figure 4**



## Supplementary Figure 5



12 most frequently occuring 5-mers with AUA (>55%)				
5-mer	p-values			
UCAUA	0.00126			
CAUAU	0.00126			
GUAUA	0.0013			
<u>AUAU</u> G	0.0013			
UGAUA	0.0013			
ACAUA	0.00133			
AUACA	0.00133			
UUAUA	0.00152			
U <u>AUAU</u>	0.00152			
A <u>AUAU</u>	0.00156			
AUAUU	0.00156			
AUAUA	0.0016			

D

Top 15 7-mers with central -AUA- element				
7-mer	p-values			
GC <u>AUAU</u> U	0.00135			
ACAUAGC	0.00193			
GCAUAUA	0.00344			
UCAUAUU	0.00397			
UCAUAUG	0.00575			
UGAUACU	0.00575			
UCAUAAU	0.00641			
CCAUAUA	0.00641			
GG <u>AUAU</u> A	0.00678			
UG <u>AUAU</u> U	0.00781			
UC <u>AUAU</u> A	0.00781			
UUAUACC	0.00781			
GA <u>AUAU</u> U	0.00893			
GU <u>AUAU</u> U	0.00961			
AC <u>AUAU</u> U	0.00961			